BIOTRONIK Home Monitoring Reduces All-Cause Mortality in ICD Patients
Newly Published TRUECOIN Meta-Analysis Shows Home Monitoring Saves Lives by Slowing Heart Failure Progression
Results now published in the European Heart Journal show BIOTRONIK Home Monitoring® reduces the risk of all-cause mortality in ICD patients after one year by 38 percent. The TRUECOIN study also found a 36 percent reduction in the combined risk of all-cause mortality and hospitalization for worsening heart failure.1
Cardiovascular disease is the number one cause of death globally.2 Implantable cardioverter defibrillators (ICDs) control life-threatening arrhythmias, including those that cause sudden cardiac arrest. Some ICD patients also have heart failure, which affects 26 million people worldwide,3 or two to three percent of the adult population.
The TRUECOIN study pooled 2,405 patients from the TRUST4, ECOST5 and IN-TIME6 trials. The IN-TIME study showed more than a 50 percent risk reduction in all-cause mortality in ICD and CRT-D (cardiac resynchronization therapy defibrillator) patients with symptomatic heart failure. Based on these results, the European Society of Cardiology (ESC) recommends remote monitoring with the IN-TIME approach for this patient group in its latest heart failure guidelines.
The new meta-analysis extends the observed mortality benefit to a broader range of ICD patients with less severe heart failure. Furthermore, TRUECOIN identified the prevention of heart failure exacerbation as the underlying clinical mechanism of the observed benefits. Daily automatic transmission and analysis of a multiparameter data set make it possible to detect changes in heart failure status.
Other clinical studies like REM-HF, presented at ESC 2016, investigated remote monitoring systems and devices from other manufacturers, and have not found clinical benefits with remote monitoring. Dr. Gerhard Hindricks, lead investigator of TRUECOIN and IN-TIME, as well as president of the European Heart Rhythm Association, explained why TRUECOIN and IN-TIME show mortality benefits while other studies have not.
“It matters which technology you use,” commented Dr. Hindricks, Leipzig Heart Center, Germany. “The IN-TIME and TRUECOIN results show that BIOTRONIK Home Monitoring leads to improved clinical outcomes for patients. I believe this is due to differences in manufacturers’ technology, the data collected and clinic workflow.”
Concurrent with the publication of the TRUECOIN results, another study by Varma et al. investigating battery longevity and transmission reliability of Home Monitoring devices was published in Europace. The TRUST post-hoc analysis shows that Home Monitoring conserves battery longevity despite daily data transmissions. Results endorse the Heart Rhythm Society (HRS) Class 1A recommendation that remote monitoring be employed for battery conservation. The study also finds daily Home Monitoring transmissions to be highly reliable.7
1 Hindricks G et al. European Heart Journal. 2017, May 10. doi: https://doi.org/10.1093/eurheartj/ehx015
2 WHO Cardiovascular Diseases Fact Sheet, 2016.
3 CDC Heart Failure Fact Sheet, 2016.
4 Varma N et al. Europace. 2011, 13 (3).
5 Guedon-Moreau L et al. European Heart Journal. 2013, 34 (8).
6 Hindricks G et al. Lancet. 2014, 384 (9943).
7 Varma N et al. Europace. 2017, May 10. doi: https://doi.org/10.1093/europace/eux059
BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.